Which are the causes of Acute myelogenous leukemia (AML)?

TL;DR: Acute myelogenous leukemia (AML) is primarily caused by acquired genetic mutations in bone marrow stem cells that lead to the uncontrolled production of abnormal, immature white blood cells. While the exact trigger for these mutations is often unknown, factors such as previous chemotherapy, radiation exposure, and certain genetic syndromes can increase the risk of developing Acute myelogenous leukemia (AML).

What causes the genetic mutations in Acute myelogenous leukemia (AML)?

The development of Acute myelogenous leukemia (AML) is a multi-step process. Think of the bone marrow as a factory; in AML, the "blueprints" (DNA) in the stem cells are damaged. Over time, these cells accumulate mutations that stop them from maturing properly. While we know these mutations occur in genes like FLT3, NPM1, and DNMT3A, the initial "spark" that causes these errors is frequently a random biological accident during cell division rather than an inherited trait.

What are the known risk factors for Acute myelogenous leukemia (AML)?

Researchers distinguish between "causes" (the direct mechanism of disease) and "risk factors" (elements that increase the likelihood of the disease occurring). Known risk factors for Acute myelogenous leukemia (AML) include:

• Prior Cancer Treatment: Exposure to specific chemotherapy drugs (like alkylating agents) or radiation therapy.


• Genetic Conditions: Inherited syndromes such as Down syndrome, Fanconi anemia, or Li-Fraumeni syndrome.


• Chemical Exposure: Long-term, high-level exposure to chemicals like benzene.


• Blood Disorders: Pre-existing conditions like myelodysplastic syndromes (MDS) or myeloproliferative neoplasms.


• Smoking: Tobacco use is a well-documented environmental risk factor linked to an increased incidence of AML.

Is the etiology of Acute myelogenous leukemia (AML) fully understood?

While we have identified many of the genetic drivers behind Acute myelogenous leukemia (AML), the etiology remains an active area of research. We do not yet fully understand why some people with these risk factors develop the disease while others do not. Current clinical research is heavily focused on "clonal hematopoiesis of indeterminate potential" (CHIP), a condition where blood cells carry mutations but have not yet progressed to full-blown leukemia, to help us predict and potentially prevent the onset of Acute myelogenous leukemia (AML).

Next steps

• Consult a hematologist-oncologist to discuss your specific genetic profile if you have been diagnosed.


• Connect with the 62 members of the DiseaseMaps.org community to share experiences and coping strategies.


• Review resources from the Leukemia & Lymphoma Society for information on clinical trials and targeted therapies.

Medical disclaimer: This content is for informational purposes only and does not constitute professional medical advice, diagnosis, or treatment.

References

• National Cancer Institute (NCI) - AML Risk Factors


• NIH Genetic and Rare Diseases Information Center (GARD)


• Orphanet: Acute Myeloid Leukemia


• The Leukemia & Lymphoma Society (LLS)